Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 20 citing articles:

Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 18
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 17
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Ryan J. Jalleh, Christopher K. Rayner, Trygve Hausken, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 957-964
Closed Access | Times Cited: 15
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 21
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta, Lakshmi Nagendra, Beatrice Anne, et al.
Obesity Science & Practice (2024) Vol. 10, Iss. 2
Open Access | Times Cited: 9
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 6
Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)
Yuxiang Tu, Haoyong Yu
Metabolism and Target Organ Damage (2025)
Open Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access
Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
Clare Buckeridge, Nikolaos Tsamandouras, Santos Carvajal‐Gonzalez, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3155-3166
Closed Access | Times Cited: 3
Advances in small-molecule insulin secretagogues for diabetes treatment
Jingqian Su, Jingran Xu, Shan Hu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117179-117179
Open Access | Times Cited: 3
Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis
Hareer Fatima, Hussain Sohail Rangwala, Muhammad Saqlain Mustafa, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3567-3578
Open Access | Times Cited: 9
Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112
Jingchao Sun, Ying Xiao, Xing Wei, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116965-116965
Open Access | Times Cited: 2
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
Neeta B. Amin, Robert Frederich, Nikolaos Tsamandouras, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces
Sophia M. N. Hönig, Florian Flachsenberg, Christiane Ehrt, et al.
Journal of Computer-Aided Molecular Design (2024) Vol. 38, Iss. 1
Open Access | Times Cited: 1
Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?
Ryan A. Lafferty, Peter R. Flatt, Victor A. Gault, et al.
Journal of Endocrinology (2024) Vol. 262, Iss. 2
Open Access | Times Cited: 1
GLP-1R mediates idebenone-reduced blood glucose in mice
Xin Zhao, Qingxuan Zeng, Siting Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117202-117202
Open Access | Times Cited: 1
Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes
Daryl J. Fediuk, Donal Gorman, Stephanie‐An Stoddard, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 4, pp. 449-460
Open Access | Times Cited: 2
Toxicology profile of a novel GLP1 receptor biased agonist-SAL0112 in nonhuman primates
Jingchao Sun, Ying Xiao, Xuefeng Hu, et al.
Toxicology and Applied Pharmacology (2024) Vol. 492, pp. 117125-117125
Closed Access
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
Rajmohan Seetharaman, Swarnima Pandit
Journal of Basic and Clinical Physiology and Pharmacology (2023) Vol. 35, Iss. 1-2, pp. 1-4
Closed Access | Times Cited: 1
Page 1

Scroll to top